Table 3.
Details of AMI AE due to PD-1/PDL-1 inhibitors
| Total number of AMI AEs | 13 |
| PD-1/PDL-1 inhibitor used | |
| Nivolumab | 9 (69.23%) |
| Pembrolizumab | 2 (15.38%) |
| Atezolizumab | 1 (7.69%) |
| Durvalumab | 1 (7.69%) |
| Indication for PD-1/PDL-1 use | |
| Lung cancer | 10 (76.92%) |
| Head and neck cancer | 1 (7.69%) |
| Malignant melanoma | 1 (7.69%) |
| Unknown | 1 (7.69%) |
| Type of reaction | |
| Serious | 13 (100%) |
| Sex | |
| Male | 8/11 (72.72%) |
| Female | 3/11 (27.27%) |
| Median age, years (range, min-max) | 78.5 (50–88); n=10 |
| Outcome | |
| Died | 1 (7.69%) |
| Hospitalised | 4 (30.76%) |
| Life threatening | 2 (15.38%) |
| Other outcome | 6 (46.15%) |
| Reporter | |
| Healthcare professional | 13 (100%) |
| Year initial report received | |
| 2016 | 1 (7.69%) |
| 2017 | 3 (23.07%) |
| 2018 | 4 (30.76%) |
| 2019 | 4 (30.76%) |
| 2020 | 1 (7.69%) |
| Region of origin of AE | |
| Asia | 10 (76.92%) |
| Europe | 2 (15.38%) |
| Americas | 1 (7.69%) |
| Suspected drug | |
| PD-1/PDL-1 inhibitor | 11 (84.61%) |
| PD-1/PDL-1 inhibitor + ≥1 | 2 (15.38%) |
AEs, adverse events; AMI, atypical mycobacterial infection; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1.